Statin therapy for hyperlipidemia

JAMA

Volumn 310, Issue 11, 2013, Pages 1184-1185

  McEvoy, John W ^a   Blumenthal, Roger S ^a   Blaha, Michael J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERIAL REVASCULARIZATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG RESPONSE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LETTER; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION;

EID: 84884200567     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.276734     Document Type: Letter

References (5)

1. Sugerman DT. Statins [JAMA Patient Page]. JAMA. 2013;309(13):1419.
2. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
3. Minder CM, Blaha MJ, Horne A, Michos ED, Kaul S, Blumenthal RS. Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med. 2012;125(5):440-446.
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
5. Mihaylova B, Emberson J, Blackwell L, et al Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.